MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP
The active component of MC2-25 Cream is a di-peptide, which is formulated in MC2 Therapeutics' proprietary formulation and drug delivery system PAD Technology.
- The active component of MC2-25 Cream is a di-peptide, which is formulated in MC2 Therapeutics' proprietary formulation and drug delivery system PAD Technology.
- The trial is a Phase 2, randomized, multicenter, double-blind, parallel-group trial in subjects with CKD-aP stages 3-5.
- Fueled by an entrepreneurial mindset and creativity, MC2 Therapeutics aims to set new standards in treatment satisfaction for people with skin conditions.
- For additional information on MC2 Therapeutics Group, pleasevisit www.mc2therapeutics.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/mc2-therapeutics-announces-init...